Switch theme
Sign up to access all valuation multiples
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
2014
5.9K+
LTM Revenue $2.1B
LTM EBITDA $478M
$8.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medpace has a last 12-month revenue of $2.1B and a last 12-month EBITDA of $478M.
In the most recent fiscal year, Medpace achieved revenue of $2.1B and an EBITDA of $476M.
Medpace expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medpace valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.1B | XXX | XXX | XXX |
| Gross Profit | $432M | $525M | XXX | XXX | XXX |
| Gross Margin | 23% | 25% | XXX | XXX | XXX |
| EBITDA | $363M | $476M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 23% | XXX | XXX | XXX |
| Net Profit | $245M | $283M | XXX | XXX | XXX |
| Net Margin | 13% | 13% | XXX | XXX | XXX |
| Net Debt | $21.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medpace's stock price is $305.
Medpace has current market cap of $9.2B, and EV of $8.7B.
See Medpace trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.7B | $9.2B | XXX | XXX | XXX | XXX | $12.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medpace has market cap of $9.2B and EV of $8.7B.
Medpace's trades at 4.1x LTM EV/Revenue multiple, and 18.2x LTM EBITDA.
Analysts estimate Medpace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medpace and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $8.7B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.2x | XXX | XXX | XXX |
| P/E | 22.8x | XXX | XXX | XXX |
| P/E/Growth | 10.4x | XXX | XXX | XXX |
| EV/FCF | 15.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedpace's NTM/LTM revenue growth is 4%
Medpace's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $35K for the same period.
Over next 12 months, Medpace's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medpace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medpace and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $35K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medpace acquired XXX companies to date.
Last acquisition by Medpace was XXXXXXXX, XXXXX XXXXX XXXXXX . Medpace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medpace founded? | Medpace was founded in 2014. |
| Where is Medpace headquartered? | Medpace is headquartered in United States of America. |
| How many employees does Medpace have? | As of today, Medpace has 5.9K+ employees. |
| Who is the CEO of Medpace? | Medpace's CEO is Mr. August J. Troendle, M.D.. |
| Is Medpace publicy listed? | Yes, Medpace is a public company listed on NAS. |
| What is the stock symbol of Medpace? | Medpace trades under MEDP ticker. |
| When did Medpace go public? | Medpace went public in 2016. |
| Who are competitors of Medpace? | Similar companies to Medpace include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Medpace? | Medpace's current market cap is $9.2B |
| What is the current revenue of Medpace? | Medpace's last 12-month revenue is $2.1B. |
| What is the current EBITDA of Medpace? | Medpace's last 12-month EBITDA is $478M. |
| What is the current EV/Revenue multiple of Medpace? | Current revenue multiple of Medpace is 4.1x. |
| What is the current EV/EBITDA multiple of Medpace? | Current EBITDA multiple of Medpace is 18.2x. |
| What is the current revenue growth of Medpace? | Medpace revenue growth between 2023 and 2024 was 12%. |
| Is Medpace profitable? | Yes, Medpace is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
